No abstract available
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antineoplastic Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Drug Administration Schedule
-
Female
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Fusion Proteins, bcr-abl / genetics*
-
Fusion Proteins, bcr-abl / metabolism
-
Gene Expression
-
Germany
-
Humans
-
Imatinib Mesylate / therapeutic use*
-
Infant
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Male
-
Protein Kinase Inhibitors / therapeutic use*
-
RNA, Messenger / antagonists & inhibitors
-
RNA, Messenger / genetics*
-
RNA, Messenger / metabolism
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
BCR-ABL1 fusion protein, human
-
Protein Kinase Inhibitors
-
RNA, Messenger
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl